Compare AbCellera Biologics Inc (ABCL) vs Endeavour Silver Corp (EXK) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Endeavour Silver (EXK) trades at $8.51, down 0.58% on the day, with a neutral technical signal and bearish moving averages. The company reported strong Q1 2026 results with earnings of $0.21 per share beating expectations, driven by record production. However, full-year 2025 showed a net loss of $119.10 million despite revenue growth. Recent news highlights high-grade mineralization discoveries at its Terronera mine, supporting future production potential.

The outlook is mixed: analyst consensus is strongly bullish (78.57% buy ratings), but profitability remains a concern with negative margins. Key risks include execution on growth projects and silver price volatility. Upside catalysts hinge on sustained operational improvements and favorable commodity markets.